ACS Nano,
Journal Year:
2020,
Volume and Issue:
14(10), P. 12281 - 12290
Published: Oct. 6, 2020
The
three
design
criteria
of
anticancer
nanomedicines
to
improve
efficacy
and
reduce
toxicity
have
been
debated
for
decades:
(1)
Nanomedicines
increase
drug
accumulation
through
enhanced
permeability
retention
(EPR)
in
tumors
efficacy.
(2)
Long
systemic
circulation
with
high
plasma
concentration
reduces
reticuloendothelial
system
(RES)
clearance
decreases
the
normal
organs
toxicity,
enhance
EPR
effect.
(3)
A
universal
nanodelivery
platform
based
on
long
can
be
developed
deliver
different
drugs.
Although
these
repeatedly
confirmed
preclinical
xenograft
cancers,
majority
failed
clinical
efficacy,
while
efficacies/safety
successful
are
inconsistent
criteria.
First,
debate
over
tumor
may
mixed
two
questions
missed
more
clinically
relevant
comparisons
versus
free
When
compared
tissues,
has
both
mouse
human
cancers.
However,
not
drugs,
despite
outstanding
improvement
Heterogeneity
cancers
occurs
small/large
molecules
nanomedicines,
which
cannot
fully
explain
poor
translation
nanomedicines'
from
cancer
models
patients.
Second,
long-circulation
nanomedicine
should
used
as
a
criterion
because
it
does
further
by
patients
nor
universally
distribution
organs.
In
contrast,
change
tissue
alter
efficacy/safety.
Third,
that
uses
same
drugs
is
feasible.
Rather,
drug-specific
systems
required
overcome
intrinsic
shortcomings
delivered
determined
physicochemical,
pharmacokinetic,
pharmacodynamic
properties
nanocarriers
their
International Journal of Nanomedicine,
Journal Year:
2018,
Volume and Issue:
Volume 13, P. 4727 - 4745
Published: Aug. 1, 2018
Abstract:
Advances
in
nanomedicine
have
become
indispensable
for
targeted
drug
delivery,
early
detection,
and
increasingly
personalized
approaches
to
cancer
treatment.
Nanoparticle-based
drug-delivery
systems
overcome
some
of
the
limitations
associated
with
traditional
cancer-therapy
administration,
such
as
reduced
solubility,
chemoresistance,
systemic
toxicity,
narrow
therapeutic
indices,
poor
oral
bioavailability.
field
include
“smart”
or
multiple
levels
targeting,
extended-release
that
provide
additional
methods
overcoming
these
limitations.
More
recently,
idea
combining
smart
delivery
has
emerged
hopes
developing
highly
efficient
nanoparticles
improved
bioavailability,
safety
profiles.
Although
functionalized
been
studied
extensively,
there
remain
gaps
literature
concerning
their
application
We
aim
an
overview
therapies,
well
introduce
innovative
advancements
nanoparticle
design
incorporating
principles.
With
growing
need
medicine
treatment,
potential
enhance
chemotherapy
patient
adherence,
treatment
outcomes
patients.
Keywords:
nanomedicine,
systems,
extended
release,
Pharmaceutics,
Journal Year:
2020,
Volume and Issue:
12(4), P. 298 - 298
Published: March 25, 2020
Conventional
chemotherapy
is
the
most
common
therapeutic
method
for
treating
cancer
by
application
of
small
toxic
molecules
thatinteract
with
DNA
and
causecell
death.
Unfortunately,
these
chemotherapeutic
agents
are
non-selective
can
damage
both
healthy
tissues,
producing
diverse
side
effects,
andthey
have
a
short
circulation
half-life
limited
targeting.
Many
synthetic
polymers
found
as
nanocarriers
intelligent
drug
delivery
systems
(DDSs).
Their
unique
physicochemical
properties
allow
them
to
carry
drugs
high
efficiency,
specificallytarget
tissue
control
release.
In
recent
years,
considerable
efforts
been
made
design
smart
nanoplatforms,
including
amphiphilic
block
copolymers,
polymer-drug
conjugates
in
particular
pH-
redox-stimuli-responsive
nanoparticles
(NPs).
This
review
focused
on
new
generation
polymer-based
DDSs
specific
chemical
functionalities
that
improve
their
hydrophilicity,
loading
cellular
interactions.Recentlydesigned
multifunctional
used
therapy
highlighted
this
review.
Nanomaterials,
Journal Year:
2022,
Volume and Issue:
12(24), P. 4494 - 4494
Published: Dec. 19, 2022
Current
research
into
the
role
of
engineered
nanoparticles
in
drug
delivery
systems
(DDSs)
for
medical
purposes
has
developed
numerous
fascinating
nanocarriers.
This
paper
reviews
various
conventionally
used
and
current
carriage
system
to
deliver
drugs.
Due
drawbacks
conventional
DDSs,
nanocarriers
have
gained
immense
interest.
Nanocarriers
like
polymeric
nanoparticles,
mesoporous
nanomaterials,
carbon
nanotubes,
dendrimers,
liposomes,
metallic
nanomedicine,
nanomaterials
are
as
targeted
at
specific
sites
affected
areas
body.
Nanomedicine
rapidly
grown
treat
certain
diseases
brain
cancer,
lung
breast
cardiovascular
diseases,
many
others.
These
nanomedicines
can
improve
bioavailability
absorption
time,
reduce
release
eliminate
aggregation,
enhance
solubility
blood.
introduced
a
new
era
by
refining
therapeutic
directories
energetic
pharmaceutical
elements
within
nanoparticles.
In
this
context,
vital
information
on
was
reviewed
conferred
towards
ailments.
All
these
were
tested
vitro
vivo.
coming
years,
human
health
more
effectively
adding
advanced
techniques
system.
ACS Nano,
Journal Year:
2020,
Volume and Issue:
14(10), P. 12281 - 12290
Published: Oct. 6, 2020
The
three
design
criteria
of
anticancer
nanomedicines
to
improve
efficacy
and
reduce
toxicity
have
been
debated
for
decades:
(1)
Nanomedicines
increase
drug
accumulation
through
enhanced
permeability
retention
(EPR)
in
tumors
efficacy.
(2)
Long
systemic
circulation
with
high
plasma
concentration
reduces
reticuloendothelial
system
(RES)
clearance
decreases
the
normal
organs
toxicity,
enhance
EPR
effect.
(3)
A
universal
nanodelivery
platform
based
on
long
can
be
developed
deliver
different
drugs.
Although
these
repeatedly
confirmed
preclinical
xenograft
cancers,
majority
failed
clinical
efficacy,
while
efficacies/safety
successful
are
inconsistent
criteria.
First,
debate
over
tumor
may
mixed
two
questions
missed
more
clinically
relevant
comparisons
versus
free
When
compared
tissues,
has
both
mouse
human
cancers.
However,
not
drugs,
despite
outstanding
improvement
Heterogeneity
cancers
occurs
small/large
molecules
nanomedicines,
which
cannot
fully
explain
poor
translation
nanomedicines'
from
cancer
models
patients.
Second,
long-circulation
nanomedicine
should
used
as
a
criterion
because
it
does
further
by
patients
nor
universally
distribution
organs.
In
contrast,
change
tissue
alter
efficacy/safety.
Third,
that
uses
same
drugs
is
feasible.
Rather,
drug-specific
systems
required
overcome
intrinsic
shortcomings
delivered
determined
physicochemical,
pharmacokinetic,
pharmacodynamic
properties
nanocarriers
their
